ALKEM · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 48/100 — Quality 67 · Valuation 25 · Growth 45 · Momentum 50
| Share price | ₹5,653.50 |
| Market cap | ₹67,429 Cr |
| P/E ratio | 28.4 |
| P/B ratio | 5.1 |
| ROE | 21.7% |
| ROCE | 19.0% |
| Dividend yield | 0.90% |
| Book value | ₹1,116.26 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹14,712 Cr | ₹2,351 Cr | 20.0% |
| 2025 | ₹12,965 Cr | ₹2,215 Cr | 19.0% |
| 2024 | ₹12,668 Cr | ₹1,811 Cr | 18.0% |
| 2023 | ₹11,599 Cr | ₹1,007 Cr | 14.0% |
| 2022 | ₹10,634 Cr | ₹1,680 Cr | 19.0% |
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neu